EXACT Therapeutics AS announces interim results for first half 2021

Written By Guest User

OSLO/LONDON, SEPTEMBER 22nd 2021

September 22nd 2021: EXACT Therapeutics AS ('EXACT-Tx') announces its interim results for the first half 2021.

The Interim Report for half year 2021 is also available on the company's website: www.exact-tx.com

About EXACT-Tx

EXACT-Tx is a clinical stage Norwegian biotech company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug enhancement – with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. www.exact-tx.com

Guest User
Previous

EXACT Therapeutics AS - EGM notice
Next

Updated: May 30th 2021 — Notice of Annual General Meeting 2021